DISCERNING THE MAUVE FACTOR, PART 2
Woody R. McGinnis, MD; Tapan Audhya, PhD; William J. Walsh, PhD; James A. Jackson, PhD; John McLaren-Howard, DSc, FACN; Allen Lewis, MD; Peter H. Lauda, MD; Douglas M. Bibus, PhD; Frances Jurnak, PhD; Roman Lietha, MD; Abram Hoffer, MD, PhD

"Mauve Factor" was once mistaken for tryptophan but is the hydroxylamino hemoporphyrin (HPL). Treatment with nutrients—particularly vitamin B6 and zinc—reduces urinary excretion of HPL and improves diverse neurobehavioral symptoms in subjects with elevated urinary HPL. Heightened HPL excretion classically associates with emotional stress, which in turn is known to associate with oxidative stress. For this review, markers for nutritional status and for oxidative stress were examined in relationship to urinary HPL.

In cohorts with mixed diagnoses, 24-hour urinary HPL correlated negatively with vitamin B6, activity and zinc concentration in red cells (P<.0001). Above-normal HPL excretion corresponded to subnormal vitamin B6 activity and subnormal zinc with remarkable consistency. HPL correlated inversely with plasma GSH and red-cell catalase, and correlated directly with plasma nitric oxide (P<.0001). Thus, besides implying proportionate needs for vitamin B6 and zinc, HPL is a promising biomarker for oxidative stress. HPL is known to cause non-erythroid heme depression, which lowers zinc, increases nitric oxide, and increases oxidative stress.

Administration of prednisone reportedly provoked HPL excretion in animals. Since adrenocorticoid (and catecholamine) stress hormones mediate intestinal permeability, urinary HPL was examined in relationship to urinary indicans, presumptive marker for intestinal permeability. Urinary HPL associated with higher levels of indicans (P<.0001). Antibiotics reportedly reduce HPL in urine, suggesting an enterogetic role in production. Potentially, gut is reservoir for HPL or its precursor, and stress-related changes in intestinal permeability mediate systemic and urinary concentrations. (Altern Ther Health Med. 2008;14(3):56-62.)


The biological origin of HPL (Mauve Factor) is unknown. Over decades, serious consideration has been given to derivation from (1) dietary sources, (2) heme, (3) porphobilinogen (PBG), or (4) porphyrins. A known polymorphism for coproporphyrinogen oxidase (CPOX), as yet unexamined in relation to Mauve, presents a potential genetic basis for increased HPL excretion, invites modulation by specific environmental toxins, and invokes an enterogetic role in production of HPL.

Ingestion of large amounts of dietary sources of the pyrrole moiety—coffee, tea, cola drinks, chlorophyll, tobacco, tryptophan, vitamin B12—did not increase HPL excretion in hospitalized psychiatric patients. Another potential source of pyrrole, D-lysergic diethylamide (LSD), did increase HPL excretion in 20% of subjects.

Pfeiffer suggested that HPL results from breakdown of heme, and Irvine identified a distinctive triad of urobilinoids in the stool of high-Mauve subjects which were possibly consistent with derivation of HPL from microbial degradation of bile pigments. Irvine was unable to produce HPL from heme, bilirubin, or bile pigments under mild laboratory conditions and found

Disclosure
The following authors affiliate with commercial laboratories that perform HPL assay: Audhya (Vitamin Diagnostics, Inc, Cliffwood Beach, New Jersey); Jackson (Bio-Center Laboratory, Wichita, Kansas); and McLaren-Howard (BioLab Medical Unit, London).
that a large dose of hemoglobin (1.6 kg of blood sausage over 48 hours) produced no effect on HPL excretion.9

Irvine hypothesized that HPL is a metabolite of PBG or porphyrins from the heme biosynthetic pathway, citing the structural similarity of these compounds to HPL, the porphyrinogenicity of HPL, and very high levels of HPL in acute intermittent porphyria (AIP).3 The side-chains of PBG correspond exactly to HPL once they are decarboxylated and deaminated, and an endogenous enzyme is known to convert PBG to the corresponding hydroxylactam. Irvine included as precursor candidates all porphyrins with a methyl, vinyl, or ethyl group found in hemo-configuration on ring 1.1 Response to a large oral dose of aminolevulinic acid (ALA) (1.5 g) did double urinary HPL over baseline in one subject for several days.10 Irvine failed to produce HPL from porphyrins under mild laboratory conditions.9

Of all the porphyrins, isocoproporphyrin is most homologous to HPL.11 Isocoproporphyrins are an abnormal series of porphyrins from altered human heme biosynthesis.12,13 A polymorphism for CPOX increases isocoproporphyrins, as do toxins such as mercury,14 diazinon,16 and hexachlorobenzene.17 Suggestively, urinary coproporphyrin concentrations were greater in high-Mauve schizophrenics than other schizophrenics,9 and intraperitoneal injection of rats with 0.65 μmol/kg of HPL (Cutler's low dose, as discussed in part 1 of this article) quintupled urinary coproporphyrins.18

The formation of isocoproporphyrin from altered human heme biosynthesis requires participation of gut flora. Altered host CPOX produces dehydroisocoproporphyrinogen, which is degraded by gut flora to produce isocoproporphyrin in stool.13,14,15 If, as Irvine suggested, isocoproporphyrin is a precursor to HPL, then either host or microbe16 could effect the final conversion from isocoproporphyrin. But the preceding step—dehydroisocoproporphyrinogen to isocoproporphyrin—is microbial.

Preliminary evidence does suggest bacterial involvement in the formation of Mauve. Oral tetracycline reversibly abolished urinary HPL excretion in 4 previously Mauve-positive subjects. Oral dosing with kanamycin, a non-absorbable antibiotic, reversibly abolished or sharply reduced urinary HPL in 9 subjects.19

MAUVE AND THE GUT

There has been no quantification of HPL in stool or direct measurement of intestinal permeability of high-Mauve subjects, but multiple observations suggest that intestinal permeability modulates HPL excretion in urine. As these facts are considered, it should be kept in mind that Mauve not only is associated with neurobehavioral symptoms, but abdominal signs and symptoms exist in many high-Mauve subjects. Abdominal tenderness was reported in a large percentage of high-Mauve subjects,20 and Pfeiffer associated Mauve with sharp abdominal pains, as "stitch-in-side."21,22 Schizophrenics23 and autistics24-27 have more abdominal symptoms, and abdominal pain is characteristic of AIP.

It is known that zinc deficiency results in intestinal epithelial damage and increased permeability mediated by greater intestinal NO.28 Since urinary HPL associates with zinc deficiency, HPL might be expected to associate with intestinal permeability.

Irvine observed that laxatives and enemas increase urinary HPL.1 The types of enemas and laxatives were not specified, but the range of possibilities would appear to increase intestinal permeability. Magnesium sulfate29 and bisacodyl30 significantly increase intestinal permeability. Soap-suds or tap-water enemas result in epithelial loss,31 which would be expected to increase intestinal permeability. The effect of laxatives and enemas suggests that intestinal permeability affects urinary HPL.

To explain the clinical observation that HPL excretion and stress are associated, Sohler specifically proposed that urinary excretion of HPL relates to a "stress-induced anomaly of intestinal permeability which permits these pyrroles to get into the systemic circulation."32-34 It is well established that stress increases intestinal permeability. One hour of water-avoidance stress35 or 4 hours of restraint stress36 significantly increased intestinal permeability in rats. Psychosocial stress results in intestinal inflammation and greater intestinal permeability in humans.37-39 More specifically, emotional stress increases urinary excretion of compounds normally retained in the bowel, including bilirubin metabolites34-35 and indoles40-41 from bacterial degradation of tryptophan.

The permeabilized intestinal epithelium of stressed rodents is characterized by greater numbers of bacteria adhering to or penetrating bowel epithelium, infiltration by mononuclear cells,36,37 mast cell activation, and depletion of mucus.42-45 Catecholamines and glucocorticoids—the so-called "stress hormones"—increase many-fold during stress. Experimentally, administration of stress hormones duplicates the effects of experimental stress on intestine.

Application of norepinephrine to sheets of large bowel increased bacterial adherence within 30 minutes.46 Intestinal epithelial permeability is increased by glucocorticoid injection and mediated by glucocorticoid receptors.47 Central or peripheral injection of corticotropin releasing factor (CRF) mimics stress-induced degranulation of mast cells and increased permeability in colon.48-50 Dexamethasone injections of rats decreased IgA and increased bacterial adherence to epithelium within 24 hours.48

Irvine's attempts to provoke HPL in animals with a number of treatments were futile, with one notable exception: urinary HPL increased significantly in Sprague-Dawley rats and female hyperprolinemic (PRO/Re) mice treated with prednisone.51 Other mechanisms—including porphyrinogenic—are possible, but the response to prednisone is consistent with a permeability effect on HPL excretion.

Roman Lietha presented data that suggested an association between urinary HPL and indicans in 154 patients at a Princeton BioCenter conference in 1988. The indicans test is a qualitative assay for urinary indoles, which result from enterobial degradation of tryptophan. It is known that intestinal permeability associates with increased accumulation of tryptophan in intestinal mucous.52
Indicans correlate poorly with dietary protein and small bowel flora but do associate with enteric protein loss, which in turn associates with intestinal permeability. Urinary indicans, while lacking specificity, would be expected to associate with intestinal permeability. Data from a mixed cohort of 2726 subjects from the Biocenter Laboratory in Wichita, Kansas, were examined to determine if a relationship exists between indicans and HPL in urine. Indicans positively correlated with HPL by colorimetric assay \( (P < 0.001) \) (Figure 1). Mauve appears to relate to gut (Figure 2).

![Figure 1](image1.png)

**Figure 1** Median Values for Colorimetric HPL Equivalents* Correlated With Indicans in Single-void Urine From Mixed Cohort of 2726 Subjects

*Normal <20 \( \mu g/dL \).

HPL values for the 4+ indicans group were skewed, necessitating use of median values for significance testing.

\( P < 0.001 \) for difference in medians of all groups.

MISLEADING LITERATURE AND OTHER OBSTACLES

After a period of initial activity, no basic research on Mauve has graced the peer-reviewed literature for many years. This inactivity contrasts rather sharply with ongoing enthusiasm for Mauve among a subgroup of nutritional practitioners and families. The disparity probably stems in part from continuing misidentification of the compound as KP. Also, HPL is a highly labile, technically challenging compound to study. What's more, only recently did the prevailing psychoanalytic paradigm open to underlying physical causation of "psychiatric" disease and the facilitative concept of oxidative stress. Finally, unwarranted negative conclusions about Mauve in the peer-reviewed literature discourage potential investigators.

An article in the *American Journal of Psychiatry* disparagingly entitled "Pyroluria: a Poor Marker in Chronic Schizophrenia" found no relationship between qualitative urinary Mauve and a presumptive list of signs and symptoms for zinc and vitamin B\(_6\) deficiency. Remarkably, the cohort had only 2 subjects with positive urine.

An article in *Clinical Science* stated unequivocally in title and abstract that Mauve, "is not causally related to schizophrenia." The text of the article softened the conclusion by stating that Mauve was "unlikely" to be causal, because no difference was found between schizophrenics and controls. The technical handling of specimens is suspect because Mauve was undetected in half of samples, at a purported detection limit of 0.25 \( \mu g/dL \). The use of subjects with active somatic illness as controls was unfortunate, because Mauve is elevated in somatic illness.

As discussed in part 1 of this article, Cutler minimized potential neurotoxicity of HPL in humans in *Pharmacology and Toxicology* on the basis of hypothetical estimates of HPL in human blood contradicted by prior published values. In addition, the article indicated that thesis work by Graham failed to demonstrate a positive correlation between HPL levels and symptom severity in schizophrenia. In fact, only 1 of 7 schizophrenics in the thesis data had above-normal urinary HPL.

Kershner reported in *Journal of Nutrition* the results of a randomized trial that sought to evaluate HPL as a screening test for response to nutrients. Twenty children with learning disability/hyperactivity received a low carbohydrate diet for 6 months, and 18 of 20 improved. Then the cohort was divided into groups of 10. One group received daily vitamin C, nicacinamide, vitamin B\(_6\), and vitamin B\(_6\) (500-750 mg); the other group received placebo. After 6 months, neither group showed additional improvement. Kershner concluded that "Kryptopyrrole [colorimetric HPL] proved invalid as a screening test for vitamin-dependent learning disorders" because pre-treatment levels did not demonstrate statistical relationship with improvement on vitamins.

The mean HPL values for the 2 groups were well within normal limits, and only 6 subjects (presumably 3 in either cohort, but not specified) had elevated HPL prior to nutrients. To compensate for the inadequate number of subjects with abnormal HPL, Kershner arbitrarily adjusted the normal range for HPL prior to statistical analysis. The choice of nutrients for the
Supplementation. Small dosages (approximately 5 mg manganese for each 30 mg of supplemental zinc) reportedly improve symptoms in some high-Mauve subjects. Serum or red-cell levels estimated in high-Mauve subjects and can aggravate symptoms. May be monitored during supplementation with manganese, element zinc daily, cellular or plasma zinc should not exceed which in excess is pro-oxidant.

Discerning the Mauve Factor, Part 2 ALTERNATIVE THERAPIES. MAY/JUN 2008, VOL. 14, NO. 3

The status and use of fatty acids in high-Mauve subjects needs elucidation. Owing to the vulnerability of double bonds to oxidative stress, both omega-3 and omega-6 fatty acid depletion might be expected in high-Mauve subjects. Preliminary data on 23 schizophrenics suggests this is the case, at least in schizophrenia. Plasma from the schizophrenics contained significantly less docosahexanoic acid (DHA, omega-3), as a percentage of total lipids, than controls. Only the 6 high-Mauve subjects from this cohort also had lower arachidonic acid (AA, omega-6) (P<.01).

A number of studies have found lower concentrations of omega-3 and omega-6 fatty acids in blood from schizophrenics, including lower red-cell membrane DHA and AA. Multiple trials report improvement in groups of schizophrenics receiving omega-3 supplementation. It is possible that Mauve identifies a subgroup which would benefit from omega-6 supplementation in combination with omega-3 or as a higher priority.

Evening primrose oil (EPO), a rich source of gamma linolenic acid (GLA), is a precursor for both AA and dihomo-gamma-linolenic acid (DGLA), immediate precursor for prostaglandin E1 (PGE-1). PGE-1 rapidly lowers intestinal permeability, including stress-induced intestinal permeability. EPO also improves zinc absorption. EPO and misoprostol, a commercial PGE-1 analogue, are logical possibilities for Mauve research.

HPL is a potentially useful screen for other biochemical abnormalities, including dysregulation of homocysteine, a neurotoxic metabolite. Cystathionine beta-synthase, which metabolizes homocysteine, is uniquely dependent on both vitamin B6 and heme as cofactors. In written communication, Allen Lewis, MD, Medical Director of Pfeiffer Treatment Center, Warrenville, Illinois, reported in 2005 that serum HCY and colormetric HPL (single-void, unadjusted) from unsupplemented autistic children seen at the Pfeiffer Treatment Center correlated significantly (N=314; P=.002). Plasma HCY associates with greater risk of cardiovascular and neurodegenerative disease.

Mauve assay may be useful in the care of subjects with strictly somatic diagnoses or in the optimization of health in subjects without out diagnoses. Mauve elevation in somatic illness presumably reflects unrecognized nutritional deficits and greater oxidative stress. In allergy, which is associated with zinc deficiency, Mauve
testing might enhance nutritional awareness. (Pfeiffer suggested allergic diathesis in association with mauve, citing the zinc requirement for histamine storage in mast cells.) Similarly, cancer associates with zinc deficiency\textsuperscript{14,15} and B\textsubscript{6} deficiency.\textsuperscript{16-18}

Corroboration of HPL as marker for zinc deficiency should be a high priority. The finding is plausible. Biotinidase, necessary for maintenance of biotin levels, is sensitive to oxidative modification, and oxidative stress is suspected to lower biotinidase in plasma.\textsuperscript{19-21} Biotin deficiency causes brain dysfunction, and subjects with partial biotinidase deficiency remain asymptomatic until stressed.\textsuperscript{22}

HPL testing is potentially useful in pregnancy, when nutritional demands are enormous and when nutritional deficits can result in fetal disease or malformation. Biotin deficiency, for example, is relatively common in pregnancy,\textsuperscript{23,24} and marginal biotin deficiency is teratogenic in mice.\textsuperscript{25} Deficiencies of biotin,\textsuperscript{26,27} zinc,\textsuperscript{28,29} and B\textsubscript{6}\textsuperscript{30,31} independently result in cleft palate in animals. Presumably, combined deficiency of these nutrients increases teratogenic risk. Hyperhomocysteinuria associates with fetal disease and malformation,\textsuperscript{32} and heme modulates neurogenesis.\textsuperscript{33} Pfeiffer associated mauve with miscarriage.\textsuperscript{34}

Predisposition to Mauve may be heritable. Some clinicians consider elevated Mauve in one family member an indication for family-wide testing. Polymorphisms favoring HPL production are considered most likely in genes for altered expression of CPOX, porphyrins, metabolism of stress hormones,\textsuperscript{35,36} or production of endogenous antioxidants such as metallothionein.\textsuperscript{37} Defective enzymes may associate with HPL, especially those that are sensitive to oxidative impairment\textsuperscript{38} and also are either B\textsubscript{6}-dependent (eg, glutamic acid decarboxylase) or zinc-dependent (eg, pyridoxal kinase).

Porphyrin profiles in high-Mauve subjects might confirm origin in the heme biosynthetic pathway, any defect of which can be magnified by factors that increase activity of ALA synthase (ALA-S). Treatment of animals with HPL significantly increased ALA-S activity.\textsuperscript{39} Presenting the intriguing possibility that an aberrant product of porphyrin metabolism may exert positive feedback on its own production. A number of toxins—especially heavy metals and alcohol—increase ALA-S activity.\textsuperscript{40}

Research is needed to confirm the relationship between HPL excretion and stress, and to more completely characterize HPL as a biomarker for oxidative stress. H\textsubscript{2}O\textsubscript{2} should be measured in high-Mauve subjects. Besides cataplasia, depression of other heme-dependent enzymes could potentiate greater oxidative stress in high-Mauve subjects. For instance, lower cytochrome p450 might confer greater sensitivity to medications or toxins.

Association of HPL excretion with stress hormones and oxidatively modified biomolecules such as 8-OHdG and isoprostane seems likely. The perspective for research in this area is provided by the understanding that emotional stress causes increased oxidation of biomolecules, including brain, as surely as do toxins or deficiency of antioxidant nutrients (as reviewed by McGinnis in 2007).\textsuperscript{18}

The biological effects of HPL are mostly unexplored, and interpretation of such studies will be abetted by accurate quantification of HPL in blood and stool. Specific microbes may associate with HPL. Downstream effects of heme suppression by HPL may be detectable in animals and high-Mauve subjects. HPL may exert significant effects on gut or brain, including hallucinosis. Associated EEG abnormality\textsuperscript{41} may normalize with Mauve suppression, but modern brain scans have eluded Mauve.

**CONCLUSION**

At the very least, this review should clarify the identity and history of Mauve (HPL). Hopefully, it will strengthen commitment to careful handling and refined laboratory approaches to urinary assay of HPL, including normalization to specific gravity or creatinine. And for the first time, herein were presented organized data that examined—and confirmed—urinary HPL as a yardstick for functional B\textsubscript{6} and zinc deficiency. The findings are congruous with clinical observations over the decades and should stimulate independent corroboration and further research.

In its search for clinically relevant biomarkers for oxidative stress, modern medicine would do well to consider urinary Mauve as a means to quantify oxidative stress and to guide the use of specific antioxidant therapies. Besides practical potential, Mauve provides an exquisite conceptual model for the interplay of oxidative stress, emotional stress, nutrients, and gut as they pertain to disease of brain and body.

**REFERENCES**


60 ALTERNATIVE THERAPIES. MAY/JUN 2008, VOL. 14, NO. 3
Discerning the Mauve Factor, Part 2


